Azitra (AZTR) Non-Current Assets (2022 - 2026)
Azitra's (AZTR) quarterly Non-Current Assets came in at $1.4 million in Q1 2026, down 32.89% YoY from $2.0 million in Q1 2025, and down 31.87% on a QoQ basis from $2.0 million in Q4 2025.
Azitra (AZTR) Non-Current Assets (2022 - 2026) Analysis & Trends
Azitra (AZTR) has 5 years of Non-Current Assets data on file, last reported at $1.4 million in Q1 2026.
- Quarterly Non-Current Assets fell 32.89% year-over-year to $1.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $7.6 million (down 14.19% YoY) and the FY2025 annual result came in at $2.0 million, down 5.84% from the prior year.
- Non-Current Assets fell to $1.4 million in Q1 2026, from $2.0 million in the prior quarter.
- In the past five years, Non-Current Assets ranged from a high of $3.0 million in Q4 2022 to a low of $1.4 million in Q1 2026.
- A 5-year average of $2.3 million and a median of $2.2 million in 2025 frame the typical range for Non-Current Assets.
- Annual changes were most pronounced in 2025 — Non-Current Assets dropped 3.38% — and 2026, when it slumped 32.89%.
- Tracing AZTR's Non-Current Assets over 5 years: stood at $3.0 million in 2022, then declined by 14.9% to $2.6 million in 2023, then slipped by 17.42% to $2.1 million in 2024, then retreated by 5.84% to $2.0 million in 2025, then plunged by 31.87% to $1.4 million in 2026.
- The last three Non-Current Assets figures came in at $1.4 million (Q1 2026), $2.0 million (Q4 2025), and $2.1 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 14.88 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 23.28 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 1.96 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 5.15 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 1.96 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 938.60 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 468.65 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 18.06 Bn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 6.80 Bn |
| 10 | Azitra | 2.44 Mn | 2.44 Mn | - | 1.47 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.47 Mn |
| Mar 31, 2026 | 1.37 Mn |
| Dec 31, 2025 | 2.01 Mn |
| Sep 30, 2025 | 2.07 Mn |
| Jun 30, 2025 | 2.16 Mn |
| Mar 31, 2025 | 2.04 Mn |
| Dec 31, 2024 | 2.13 Mn |
| Sep 30, 2024 | 2.14 Mn |
| Jun 30, 2024 | 2.55 Mn |
| Mar 31, 2024 | 2.54 Mn |
| Dec 31, 2023 | 2.58 Mn |
| Sep 30, 2023 | 2.63 Mn |
| Jun 30, 2023 | 2.99 Mn |
| Dec 31, 2022 | 3.03 Mn |